Drug Patents owned by Celgene
1. Drug name - POMALYST
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8828427 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(8 years from now) | |
| CN102333525A | CELGENE | Formulation Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
Jan, 2017
(5 years ago) | |
| EP3351240B1 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| EP2391355B1 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| EP3351240A1 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| EP2391355A2 | CELGENE | Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione |
May, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673939 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(7 months from now) | |
| US8735428 | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(7 months from now) | |
|
US8673939
(Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(1 year, 1 month from now) | |
|
US8735428
(Pediatric) | CELGENE | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(1 year, 1 month from now) | |
| US8198262 | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(2 years from now) | |
|
US8198262
(Pediatric) | CELGENE | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(3 years from now) | |
| US9993467 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(7 years from now) | |
| US10555939 | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(7 years from now) | |
|
US9993467
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(8 years from now) | |
|
US10555939
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(8 years from now) | |
|
US8828427
(Pediatric) | CELGENE | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(9 years from now) | |
Drugs and Companies using POMALIDOMIDE ingredient
Treatment: Use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG | CAPSULE;ORAL | Prescription |
| 2MG | CAPSULE;ORAL | Prescription |
| 3MG | CAPSULE;ORAL | Prescription |
| 4MG | CAPSULE;ORAL | Prescription |
2. Drug name - REVLIMID
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7855217 | CELGENE | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(2 years from now) | |
| US7465800 | CELGENE | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(4 years from now) | |
| CN1735415A | CELGENE | Methods And Compositions Using Immunomodulatory Compounds For The Treatment And Control Of Cancer And Other Diseases |
Jan, 2011
(11 years ago) | |
| CN1668296A | CELGENE | Using Selective Cytokine Inhibitory Drug For Methods And Compositions Of Treating And Controlling Cancer And Other Diseases |
Sep, 2011
(11 years ago) | |
| CN101647798A | CELGENE | Method And Composition For Treating And Processing Cancer And Other Diseases By Using Immunomodulatory Compound |
Feb, 2012
(10 years ago) | |
| CN1735412A | CELGENE | Methods And Compositions By Using Selective Cytokine Inhibitory Drug For Treating And Controlling Cancer And Other Diseases |
Aug, 2012
(10 years ago) | |
| CN1822834A | CELGENE | Methods And Compositions Using Immunomodulatory Compounds For Treating And Processing Cancer And Other Diseases |
Sep, 2012
(10 years ago) | |
| CN101316588A | CELGENE | Methods For Treatment Of Certain Leukemias By Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Jul, 2013
(9 years ago) | |
| CN1981761A | CELGENE | Method And Composite For Treating And Controlling Cancer And Other Diseases By Using Immunomodulatory Compound |
Jun, 2017
(5 years ago) | |
| CN1981761B | CELGENE | Using Immunomodulatory Compounds For Treating And Controlling Cancer And Other Diseases In The Application And Composition |
Jun, 2017
(5 years ago) | |
| CN102675281A | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Aug, 2018
(4 years ago) | |
| CN102675281B | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Aug, 2018
(4 years ago) | |
| CN102060843B | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Aug, 2018
(4 years ago) | |
| CN102060843A | CELGENE | Polymorphic Form Of 3-(4-Amino-1-Oxo-1, 3 Dihydro-Isoindol-2-Yl)-Piperidine-2, 6-Dione |
Aug, 2018
(4 years ago) | |
| CN101838261A | CELGENE | Polymorphic Form Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Aug, 2018
(4 years ago) | |
| CN101863878B | CELGENE | 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindole - -2 - Yl)--2, 6-Polymorph Of Diketone |
Aug, 2018
(4 years ago) | |
| CN101838261B | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Aug, 2018
(4 years ago) | |
| CN101863878A | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Aug, 2018
(4 years ago) | |
| CN1871003A | CELGENE | 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindol - -2 - Yl) - Piperidine - -2, A Polymorphic Form Of 6-Dione |
Aug, 2018
(4 years ago) | |
| CN1871003B | CELGENE | 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindole - -2 - Yl)--2, 6-Polymorph Of Diketone |
Aug, 2018
(4 years ago) | |
| CN1697655A | CELGENE | For Methods And Compositions Of Treating And Controlling Cancer And Other Diseases By Using Immunomodulatory Compound |
Apr, 2019
(3 years ago) | |
| CN1697655B | CELGENE | For Methods And Compositions Of Treating And Controlling Cancer And Other Diseases By Using Immunomodulatory Compound |
Apr, 2019
(3 years ago) | |
| CN102342938B | CELGENE | A Method And Composition For Treating And Controlling Solid Tumor |
May, 2023
(7 months from now) | |
| CN103495169B | CELGENE | Method And Composition For Treating And Controlling Multiple Myeloma Tumor |
May, 2023
(7 months from now) | |
| CN103495169A | CELGENE | Method And Compositions Using Immunomodulatory Compounds For Treatment And Management Of Cancers And Other Diseases |
May, 2023
(7 months from now) | |
| CN103393681A | CELGENE | Method And Composition For Treating And Controlling Multiple Myeloma |
May, 2023
(7 months from now) | |
| CN102379874B | CELGENE | Using 3 - (4-Amino - -1 - Oxo - -1, 3-Dihydro-Isoindole - -2 - Yl)--2, 6-Dione For The Treatment And Control Of Multiple Myeloma Method And Composition |
May, 2023
(7 months from now) | |
| CN103393681B | CELGENE | For Methods And Compositions For The Treatment And Management Of Multiple Myeloma |
May, 2023
(7 months from now) | |
| CN102379874A | CELGENE | Method For Treating And Controlling Multiple Myeloma By Using 3-(4-Azyl-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Diketone And Composition |
May, 2023
(7 months from now) | |
| CN102342938A | CELGENE | Method And Composition For Treating And Controlling Solid Tumour |
May, 2023
(7 months from now) | |
| EP2105135A2 | CELGENE | Pharmaceutical Compositions For Treating Cancer |
Dec, 2016
(5 years ago) | |
| EP2105135A3 | CELGENE | Pharmaceutical Compositions For Treating Cancer |
Dec, 2016
(5 years ago) | |
| EP2105135B1 | CELGENE | Pharmaceutical Compositions For Treating Cancer |
Dec, 2016
(5 years ago) | |
| EP1505973A4 | CELGENE | Methods And Compositions Using Immunomodulatory Compounds For Treatment And Management Of Cancers And Other Diseases |
Nov, 2017
(4 years ago) | |
| EP1505973B1 | CELGENE | Combinations For Treating Multiple Myeloma |
Nov, 2017
(4 years ago) | |
| EP1505973A2 | CELGENE | Combinations For Treating Multiple Myeloma |
Nov, 2017
(4 years ago) | |
| EP3042659B1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Mar, 2020
(2 years ago) | |
| EP3042659A1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Mar, 2020
(2 years ago) | |
| EP3042659B8 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Mar, 2020
(2 years ago) | |
| EP3045175A1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Mar, 2020
(2 years ago) | |
| EP3045175B1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Mar, 2020
(2 years ago) | |
| EP3045175B8 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Mar, 2020
(2 years ago) | |
| EP1667682A4 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Nov, 2020
(1 year, 10 months ago) | |
| EP1667682B1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Nov, 2020
(1 year, 10 months ago) | |
| EP1667682A2 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Nov, 2020
(1 year, 10 months ago) | |
| EP2915533B1 | CELGENE | Pharmaceutical Compositions For Treating Cancer |
May, 2023
(7 months from now) | |
| EP2915533A1 | CELGENE | Pharmaceutical Compositions For Treating Cancer |
May, 2023
(7 months from now) | |
| EP2426118B1 | CELGENE | Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Sep, 2024
(1 year, 11 months from now) | |
| EP3045176A1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Sep, 2024
(1 year, 11 months from now) | |
| EP2426118A1 | CELGENE | Methods Of Making Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione |
Sep, 2024
(1 year, 11 months from now) | |
| EP3045176B1 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Sep, 2024
(1 year, 11 months from now) | |
| EP3045176B8 | CELGENE | Polymorphic Forms Of 3-(4-Amino-1-Oxo-1,3 Dihydroisoindol-2-Yl)-Piperidine-2,6-Dione |
Sep, 2024
(1 year, 11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8404717 | CELGENE | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(6 months from now) | |
| US9056120 | CELGENE | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(6 months from now) | |
| US7189740 | CELGENE | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(6 months from now) | |
| US9393238 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(7 months from now) | |
| US9155730 | CELGENE | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(7 months from now) | |
| US9101622 | CELGENE | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(7 months from now) | |
| US9101621 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(7 months from now) | |
| US8530498 | CELGENE | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(7 months from now) | |
| US8648095 | CELGENE | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(7 months from now) | |
| US7968569 | CELGENE | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(1 year, 9 days from now) | |
| US8492406 | CELGENE | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(1 year, 9 days from now) | |
| US7468363 | CELGENE | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(1 year, 9 days from now) | |
| US8741929 | CELGENE | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(5 years from now) | |
Drugs and Companies using LENALIDOMIDE ingredient
Treatment: Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; Use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone, wherein those patients have not received previous treatment for multiple myeloma; Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, as maintenance following autologous hematopoietic stem cell transplantation (auto-hsct); Use of revlimid (lenalidomide) for the treatment of patients with multiple myeloma, in combination with dexamethasone; Use of revlimid (lenalidomide) for the treatment of previously treated marginal zone lymphoma in combination with a rituximab product; use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib; use of revlimid (lenalidomide) for the treatment of previously treated follicular lymphoma in combination with a rituximab product; Use of revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | CAPSULE;ORAL | Prescription |
| 5MG | CAPSULE;ORAL | Prescription |
| 10MG | CAPSULE;ORAL | Prescription |
| 15MG | CAPSULE;ORAL | Prescription |
| 20MG | CAPSULE;ORAL | Prescription |
| 25MG | CAPSULE;ORAL | Prescription |
3. Drug name - THALOMID
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7230012 | CELGENE | Pharmaceutical compositions and dosage forms of thalidomide |
Dec, 2023
(1 year, 2 months from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | CAPSULE;ORAL | Prescription |
| 100MG | CAPSULE;ORAL | Prescription |
| 150MG | CAPSULE;ORAL | Prescription |
| 200MG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.